Danh Pham1, Shruti Bhandari2, Christina Pinkston3, Malgorzata Oechsli4, Goetz Kloecker1. 1. Division of Hematology and Medical Oncology, James Graham Brown Cancer Center, University of Louisville, Louisville, KY. 2. Division of Hematology and Medical Oncology, James Graham Brown Cancer Center, University of Louisville, Louisville, KY. Electronic address: shruti.bhandari@louisville.edu. 3. Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences, University of Louisville, Louisville, KY. 4. James Graham Brown Cancer Center, University of Louisville, Louisville, KY.
Abstract
BACKGROUND: Since 2013, the United States Preventive Services Task Force has recommended annual screening for lung cancer in high-risk patients with low-dose computed tomography (LDCT). Current literature has provided estimates of the lung cancer screening rate and only prior to appropriate insurance coverage for LDCTs. The aim of this study was to use newly established registry data to assess the lung cancer screening rate across the United States. MATERIALS AND METHODS: Using data from the Lung Cancer Screening Registry provided by the American College of Radiology in 2016, we collected the total number of LDCT screens performed from all 1962 accredited radiographic screening sites. The 2015 National Health Interview Survey was used to estimate screening eligible smokers per United States Preventive Services Task Force criteria. These data were compared to calculate screening rate. RESULTS: In 2016, 2.0% of 7.6 million eligible smokers were screened. Rates varied by region from 1.1% in the West to 3.9% in the Northeast. The South consisted of 40.4% of eligible smokers and the most accredited screening sites (37%); however, their screening rate was among the lowest (1.7%) in the nation. Smoking cessation counseling was offered to 84% of screened current smokers prior to receiving LDCTs. CONCLUSIONS: Lung cancer screening remains heavily underutilized despite guideline recommendation since 2013, insurance coverage, and its potential to prevent thousands of lung cancer deaths annually.
BACKGROUND: Since 2013, the United States Preventive Services Task Force has recommended annual screening for lung cancer in high-risk patients with low-dose computed tomography (LDCT). Current literature has provided estimates of the lung cancer screening rate and only prior to appropriate insurance coverage for LDCTs. The aim of this study was to use newly established registry data to assess the lung cancer screening rate across the United States. MATERIALS AND METHODS: Using data from the Lung Cancer Screening Registry provided by the American College of Radiology in 2016, we collected the total number of LDCT screens performed from all 1962 accredited radiographic screening sites. The 2015 National Health Interview Survey was used to estimate screening eligible smokers per United States Preventive Services Task Force criteria. These data were compared to calculate screening rate. RESULTS: In 2016, 2.0% of 7.6 million eligible smokers were screened. Rates varied by region from 1.1% in the West to 3.9% in the Northeast. The South consisted of 40.4% of eligible smokers and the most accredited screening sites (37%); however, their screening rate was among the lowest (1.7%) in the nation. Smoking cessation counseling was offered to 84% of screened current smokers prior to receiving LDCTs. CONCLUSIONS:Lung cancer screening remains heavily underutilized despite guideline recommendation since 2013, insurance coverage, and its potential to prevent thousands of lung cancer deaths annually.
Authors: Matthijs Oudkerk; ShiYuan Liu; Marjolein A Heuvelmans; Joan E Walter; John K Field Journal: Nat Rev Clin Oncol Date: 2020-10-12 Impact factor: 66.675
Authors: Yukiko Kunitomo; Brett Bade; Craig G Gunderson; Kathleen M Akgün; Alexandria Brackett; Lynn Tanoue; Lori A Bastian Journal: J Gen Intern Med Date: 2022-07-15 Impact factor: 6.473
Authors: Krysten W Bold; Sydney Cannon; Bennie B Ford; Susan Neveu; Polly Sather; Benjamin A Toll; Lisa M Fucito Journal: Cancer Prev Res (Phila) Date: 2022-05-03
Authors: David E Gerber; Heidi A Hamann; Olivia Dorsey; Chul Ahn; Jessica L Phillips; Noel O Santini; Travis Browning; Cristhiaan D Ochoa; Joyce Adesina; Vijaya Subbu Natchimuthu; Eric Steen; Harris Majeed; Amrit Gonugunta; Simon J Craddock Lee Journal: Clin Lung Cancer Date: 2020-12-11 Impact factor: 4.840